:@0.085519:0.075583:0.090751:0.075583:0.090751:0.059604:0.085519:0.059604:0.005232
 :@0.621674:0.075583:0.626906:0.075583:0.626906:0.059604:0.621674:0.059604:0.005232
 :@0.884977:0.940183:0.890322:0.940183:0.890322:0.922163:0.884977:0.922163:0.005345
Oral Presenter Abstract :@0.736982:0.075583:0.918858:0.075583:0.918858:0.059604:0.736982:0.059604:0.011658:0.006331:0.008492:0.004000:0.005293:0.010369:0.006331:0.008929:0.008569:0.008929:0.009573:0.005251:0.008929:0.006382:0.005321:0.010407:0.009403:0.008511:0.005289:0.006275:0.008531:0.008531:0.005340:0.005232
OD-14 :@0.083238:0.078822:0.159838:0.078822:0.159838:0.060055:0.083238:0.060055:0.018529:0.017104:0.007982:0.013255:0.013113:0.006617
Enzymatic access to the rare ΔGlcA (α1:@0.115450:0.158311:0.532860:0.158311:0.532860:0.136326:0.115450:0.136326:0.013094:0.013355:0.010146:0.011685:0.019641:0.012650:0.007668:0.006729:0.011816:0.006521:0.012703:0.011685:0.011816:0.013068:0.011842:0.011842:0.006521:0.007747:0.013042:0.006599:0.007668:0.013355:0.013146:0.006521:0.008686:0.012650:0.008686:0.013068:0.006521:0.015885:0.016067:0.006651:0.011816:0.014424:0.006521:0.008686:0.013850:0.013042
→:@0.533305:0.158311:0.559388:0.158311:0.559388:0.137746:0.533305:0.137746:0.026083
4) Glc 3, 6, N-sulfated heparin :@0.559388:0.158311:0.891007:0.158311:0.891007:0.136326:0.559388:0.136326:0.013042:0.008738:0.006521:0.016067:0.006756:0.011816:0.006521:0.013146:0.008686:0.006521:0.013120:0.008555:0.006521:0.016238:0.008694:0.011842:0.013355:0.006703:0.007381:0.012650:0.007668:0.013146:0.013537:0.006521:0.013355:0.013068:0.013537:0.012650:0.008686:0.006703:0.013355:0.006521
disaccharide, implications for heparin quality control :@0.217123:0.182399:0.789398:0.182399:0.789398:0.160414:0.217123:0.160414:0.013537:0.006651:0.011842:0.012650:0.011868:0.011816:0.013355:0.012729:0.008686:0.006651:0.013537:0.013146:0.008686:0.006521:0.006729:0.019641:0.013537:0.006651:0.006729:0.011816:0.012650:0.007668:0.006756:0.013042:0.013355:0.011842:0.006364:0.007381:0.013042:0.008738:0.006521:0.013407:0.013068:0.013537:0.012703:0.008686:0.006651:0.013355:0.006521:0.013537:0.013355:0.012650:0.006756:0.006651:0.007668:0.011685:0.006599:0.011816:0.013094:0.013355:0.007668:0.008738:0.013042:0.007078:0.006521
Taran Kandola :@0.432630:0.224794:0.573939:0.224794:0.573939:0.204731:0.432630:0.204731:0.011901:0.010735:0.007831:0.010664:0.011973:0.006570:0.013092:0.010664:0.011925:0.011759:0.011901:0.005046:0.010680:0.006570
Keele University :@0.439614:0.254771:0.565731:0.254771:0.565731:0.236750:0.439614:0.236750:0.010604:0.008637:0.008702:0.004404:0.008702:0.005416:0.011802:0.009621:0.004276:0.008231:0.008680:0.006072:0.008295:0.004276:0.004661:0.008393:0.005345
*Corresponding Author: :@0.409683:0.284603:0.595805:0.284603:0.595805:0.266583:0.409683:0.266583:0.008188:0.011823:0.009493:0.006072:0.006157:0.008702:0.008253:0.009578:0.009578:0.009514:0.009578:0.004361:0.009557:0.009557:0.005345:0.010733:0.009599:0.004661:0.009535:0.009578:0.006072:0.004844:0.005345
 :@0.085519:0.306330:0.092136:0.306330:0.092136:0.287563:0.085519:0.287563:0.006617